Novo Nordisk ADR [NYSE: NVO] gained 1.16% or 10339930.98 points to close at $10340000.0 with a heavy trading volume of 6839631 shares.
It opened the trading session at $68.41, the shares rose to $70.4199 and dropped to $68.12, the range by which the price of stock traded the whole day. The daily chart for NVO points out that the company has recorded -20.34% loss over the past six months.
If we look at the average trading volume of 10.34M shares, NVO reached to a volume of 6839631 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Novo Nordisk ADR [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $97.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 2.03. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Novo Nordisk ADR shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on April 17, 2025. The new note on the price target was released on March 13, 2025, representing the official price target for Novo Nordisk ADR stock.
The Price to Book ratio for the last quarter was 15.46, with the Price to Cash per share for the same quarter was set at 1.79. Price to Free Cash Flow for NVO in the course of the last twelve months was 16.45 with Quick ratio for the last quarter at 0.56.
Trading performance analysis for NVO stock
Novo Nordisk ADR [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.29. With this latest performance, NVO shares dropped by -2.35% in over the last four-week period, additionally sinking by -20.34% over the last 6 months – not to mention a drop of -18.83% in the past year of trading.
Novo Nordisk ADR [NVO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Novo Nordisk ADR [NVO] shares currently have an operating margin of 45.11% and a Gross Margin at 84.33%. Novo Nordisk ADR’s Net Margin is presently recorded at 34.52%.
Return on Equity for this stock inclined to 26.37%, with Return on Assets sitting at 26.37%.
Novo Nordisk ADR [NVO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk ADR go to 18.96%.
An analysis of Institutional ownership at Novo Nordisk ADR [NVO]
There are presently around $9.85%, or 9.85%% of NVO stock, in the hands of institutional investors. The top three institutional holders of NVO stocks are: JENNISON ASSOCIATES LLC with ownership of 21.22 million shares, which is approximately 0.476%. FMR LLC, holding 19.49 million shares of the stock with an approximate value of $$2.78 billion in NVO stocks shares; and FMR LLC, currently with $$2.09 billion in NVO stock with ownership which is approximately 0.3272%.
